Advances in research on malaria transmission blocking vaccines

Abstract

Abstract:

This paper summarizes the common candidate antigens in transmission blocking vaccines (TBVs) and discusses the status quo of research on antigen vaccines before and after fertilization of gametes, as well as the relevant antigen vaccines in the body of mosquitoes. The hotspots in TBVs such as the study of reactionogenicity of candidate antigens and practical effects of adjuvants and their prospects are also reviewed to provide the basis for further research on malaria transmission blocking vaccines.

Key words: Malaria, Transmission blocking vaccines, Candidate antigens

摘要：

从疟疾传播阻断疫苗常见候选抗原入手，分别讨论了配子受精前的靶抗原疫苗、配子受精后的靶抗原疫苗及蚊体内的相关抗原疫苗的研究现状，并对传播阻断疫苗目前存在的热点问题，如抗原的反应原性、佐剂的应用效果等研究进展及发展前景进行综述，为进一步研究疟疾传播阻断疫苗提供参考。

关键词: 疟疾, 传播阻断疫苗, 候选抗原

CLC Number:

R531.3

ZHANG Ben-guang, LIU Li-juan, GONG Mao-qing. Advances in research on malaria transmission blocking vaccines[J]. Chines Journal of Vector Biology and Control, 2010, 21(6): 627-630.

张本光, 刘丽娟, 公茂庆. 疟疾传播阻断疫苗的研究进展[J]. 中国媒介生物学及控制杂志, 2010, 21(6): 627-630.

References

[1] World Health Organization. World malaria report
[M]. Switzerland：WHO press，2009：27.

[2] Sattabongkot J，Tsuboi T，Hisaeda H，et al. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates
[J]. Am J Trop Med Hyg，2003，69(5)：536-541.

[3] 罗树红，余新炳. 疟原虫传播阻断免疫的研究进展
[J]. 国外医学. 寄生虫病分册，1996，23(3)：100-103.

[4] Vanessa S, David CK, Kim CW. Approaches to malaria vaccine development using the retrospectroscope
[J]. Infect Immun，2009，77(8)：3130-3140.

[5] Phillips RS. Current Status of malaria and potential for control
[J]. Clin Microbiol Rev，2001，14(1)：208-226.

[6] Malkin EM， Durbin AP， Diemert DJ， et al. Phase 1 vaccine trial of Pvs25H：a transmission blocking vaccine for Plasmodium vivax malaria
[J]. Vaccine，2005，23(24)：3131-3138.

[7] Outchkourov NS，Roeffen W，Kaan A，et al. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice
[J]. Proc Natl Acad Sci USA，2008，105(11)：4301-4305.

[8] Arevalo-Herrera M， Solarte Y， Yasnot MF， et al. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade Pvs25 recombinant protein
[J]. Am J Trop Med Hyg，2005，73(5)：32-37.

[9] van Dijk MR，Janse CJ，Thompson J， et al. A central role for P48/45 in malaria parasite male gamete fertility
[J]. Cell，2001，104(1)：153-164.

[10] Gerloff DL，Creasey A，Maslau S，et al. Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum
[J]. Proc Natl Acad Sci USA，2005，102(38)：13598-13603.

[11] Milek RL， DeVries AA， Roeffen WF. Plasmodium falciparum： heterologous synthesis of the transmission-blocking vaccine candidate Pfs48/45 in recombinant vaccinia virus-infected cells
[J]. Exp Parasitol，1998，90(2)：165-174.

[12] Milek RL， Roeffen WF，Kocken CH， et al. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate，Pfs48/45，of the human malaria parasite Plasmodium falciparum produced in Escherichia coli
[J]. Parasite Immunol，1998，20(8)：377-385.

[13] Milek RL，Stunnenberg HG，Konings RN. Assembly and expression of a synthetic gene encoding the antigen Pfs48/45 of the human malaria parasite Plasmodium falciparum in yeast
[J]. Vaccine，2000，18(14)：1402-1411.

[14] Outchkourov NS，Vermunt A，Jansen J，et al. Epitope analysis of the malaria surface antigen Pfs48/45 identifies a subdomain that elicits trans-mission blocking antibodies
[J]. J Biol Chem，2007，282(23)：17148-17156.

[15] Chowdhury DC， Angv E， Kariuki T， et al. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli
[J]. PLoS One，2009，4(7)：e6352.

[16] Suwanabun N，Tsuboi T，Kaneko O，et al. Stage specific expression and genetic polymorphism of gametocyte surface proteins，Pvs47 and Pvs48/45 that are novel transmisson-blocking vaccine candidates of Plasmodium vivax
[Z]. 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene，2003：12.

[17] 刘军，冯辉，郑丽. 我国间日疟原虫传播阻断疫苗候选抗原Pvs48基因特点分析
[J]. 中国人兽共患病学报，2006，22(6)：558-560.

[18] 王冰，刘军，冯辉. 间日疟原虫传播阻断疫苗候选抗原Pvs48基因特点
[J]. 中国公共卫生，2008，24(11)：1336-1337.

[19] Eksi S，Czesny B，van Gemert GJ，et al. Malaria transmission-blocking antigen，Pfs230， mediates human red blood cell binding to exflagellating male parasites and oocyst production
[J]. Mol Microbiol，2006，61(4)：991-998.

[20] Bustamante PJ， Woodruff DC， Oh J， et al. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen，Pfs230，to induce malaria transmission-blocking immunity
[J]. Parasite Immunol，2000，22(8)：373-380.

[21] Arrighi RB， Hurd H. The role of Plasmodiumberghei ookinete proteinsin binding to basal lamina components and transformation into oocysts
[J]. Int J Parasitol，2002，32(1)：91-98.

[22] Kubler-Kielb J，Majadly F，Wu Y，et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25
[J]. Proc Natl Acad Sci USA，2007，104(1)：293-298.

[23] Kaslow DC，Shiloach J. Production，purification and immunogenicity of a malaria transmission blocking vaccine candidate：TBV25H expressed in yeast and purified using nickel-NTA agarose
[J]. Biotechnology，1994，12(5)：494-499.

[24] Leblanc R， Vasquez Y， Hannaman D， et al. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation
[J]. Vaccine，2008，26(2)：185-192.

[25] Coban C， Ken Ishii J， Anthony W， et al. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25， a Plasmodium falciparum transmission-blocking vaccine antigen
[J]. Infect Immun，2004，72(1)：584-588.

[26] Arakawa T，Komesu A，Otsuki H，et al. Nasal immunization with a malaria transmission blocking vaccine candidate， Pfs25， induces complete protective immunity in mice against field isolates of Plasmodium falciparum
[J]. Infect Immun，2005，73(11)：7375-7380.

[27] Wu Y，Ellis RD，Shaffer D，et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with Montanide ISA 51
[J]. PLoS One，2008，3：e2636.

[28] Duffy PE，Kaslow DC. A novel malaria protein， Pfs28 and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines
[J]. Infect Immun，1997，65(3)：1109-1113.

[29] Gozar MM，Price VL，Kaslow DC. Saccharomyces cerevisiae secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice
[J]. Infect Immun，1998，66(1)：59-64.

[30] Hisaeda H， Stowers AW， Tsuboi T， et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes
[J]. Infect Immun，2000，68(12)：6618-6623.

[31] 刘军，冯辉，郑丽，等. 我国云南分离株间日疟原虫传播阻断疫苗候选抗原Pvs25基因多态性分析
[J]. 中国人兽共患病杂志，2005，21(6)：458-460.

[32] 郑丽，徐卫民，刘英杰，等. 间日疟原虫传播阻断疫苗候选抗原Pvs25中国分离株高度保守
[J]. 中国寄生虫学与寄生虫病杂志，2004，22(1)：16-19.

[33] 冯辉，郑丽，刘军，等. 间日疟原虫云南分离株传播阻断疫苗候选抗原Pvs28基因多态性分析
[J]. 中国人兽共患病学报，2006，22(4)：360-362.

[34] 阎建忠，徐卫民，刘英杰，等. 间日疟原虫中国湖北分离株传播阻断疫苗候选抗原Pvs28的基因多态性分析
[J]. 寄生虫与医学昆虫学报，2003，10(4)：193-197.

[35] 李冬梅，刘英杰，刘军，等. 间日疟传播阻断疫苗Pvs25和Pvs28重组蛋白免疫活性的实验观察
[J]. 中国人兽共患病学报，2007，23(6)：598-600.

[36] 李冬梅，刘军，刘英杰，等. 间日疟原虫重组蛋白Pvs25和Pvs28免疫小鼠应答机制观察
[J]. 中国人兽共患病学报，2007，23(4)：348-350.

[37] Collins WE，Barnwell JW，Sullivan JS，et al. Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees
[J]. Am J Trop Med Hyg，2006，74(2)：215-221.

[38] Tsai YL，Hayward RE，Langer RC，et al. Disruption of Plasmodium falciparum chitinase markedly impairs parasite invasion of mosquito midgut
[J]. Infect Immun，2001，69(6)：4048-4054.

[39] Saul A，Hensmann M，Sattabongkot J，et al. Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720
[J]. Parasite Immun，2007，29(10)：525-533.

[40] Kaslow DC，Bathurst IC，Lensen T，et al. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum
[J]. Infect Immun，1994，62(12)：5576-5580.